Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
AssigneeAlexion Pharmaceuticals, Inc.
InventorsRajendra Pradhan, Xiang Gao
Life of this patent
Estimating the term…
Abstract
A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
Claims16
A method of treating a human with hypophosphatasia comprising administering to the human by subcutaneous injection two or more doses of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 1 wherein the doses are administered no more than once every three weeks and each dose comprises at least 50 mg/kg of the polypeptide.
Dependencies are inferred from the claim text.